Gail Bodner, MD
Family Medicine · Lancaster, PANPI 1720139090
Payments from drug & device makers
Across 270 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$781
- AstraZeneca$674
- AbbVie$554
- Lilly USA, LLC$416
- Amarin Pharma, Inc.$402
- GSK$288
- plus $966 from 21 others
What the payments were for
- Food & beverage$4,081100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $781 |
| AstraZeneca | 41 | $674 |
| AbbVie(2 entities) | 39 | $554 |
| Lilly USA, LLC | 21 | $416 |
| Amarin Pharma, Inc. | 50 | $402 |
| GSK | 20 | $288 |
| Novartis | 9 | $176 |
| Pfizer | 8 | $129 |
| Merck | 6 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 2 | $48 |
| Exact Sciences | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Astellas Pharma US Inc | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Biofire Diagnostics, LLC | 1 | $36 |
| Corcept Therapeutics | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Bayer | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Organon | 1 | $13 |
How this compares
$4,081 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $74,583 |
| TrulicityDulaglutide | 21 | $40,190 |
| EliquisApixaban | 18 | $30,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $25,665 |
| MounjaroTirzepatide | 17 | $25,101 |
| JardianceEmpagliflozin | 17 | $21,309 |
| RexultiBrexpiprazole | 11 | $15,624 |
| VascepaIcosapent Ethyl | 28 | $15,489 |
| LinzessLinaclotide | 16 | $11,968 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,222 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,217 |
| Icosapent Ethyl | 15 | $3,492 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,807 |
| Atorvastatin Calcium | 172 | $1,616 |
| Rosuvastatin Calcium | 87 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $781 | $74,58337 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $416 | $65,29138 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $288 | $35,88740 claims |
| PfizerEliquis | $129 | $30,43518 claims |
| Boehringer IngelheimJardiance | $15 | $21,30917 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $27 | $15,62411 claims |
| AbbVieLinzess | $554 | $11,96816 claims |
| AstraZenecaSymbicort | $674 | $4,21716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lancaster
- Stephen GoldLancaster$78K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.